ENTA - Enanta Pharmaceuticals, Inc.
NEXT EARNINGS:
May 11, 2026
EPS Est: $-0.53
|
Rev Est: $16.3M
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$20.00
DETAILS
HIGH:
$20.00
LOW:
$20.00
MEDIAN:
$20.00
CONSENSUS:
$20.00
UPSIDE:
35.59%
Market Cap:
342.45M
Volume:
297,791
Avg Volume:
291,948
52 Week Range:
4.09-17.15
Sector:
Healthcare
Industry:
Biotechnology
Beta:
0.99
Last Dividend:
$N/A
Exchange:
NASDAQ
Country:
US
Employees:
131
IPO Date:
2013-03-21
EPS (TTM):
-3.84
P/E Ratio:
-3.12
Revenue (TTM):
65.32M
Total Assets:
280.73M
Total Debt:
201.06M
Cash & Equiv:
32.30M
Rev Growth (5Y):
-11.8%
EPS Growth (5Y):
N/A
FCF Growth (5Y):
N/A
ROCE:
-32.7%
Debt/Equity:
3.11
Earnings History
| Date | EPS Actual | EPS Est | EPS Surprise | Rev Actual | Rev Est | Rev Surprise |
|---|---|---|---|---|---|---|
| 2026-02-09 | $-0.42 | $-0.54 | +22.2% | $18.6M | $16.3M | +14.5% |
| 2025-11-17 | $-0.87 | $-1.13 | +23.0% | $15.1M | $16.0M | -5.3% |
| 2025-08-11 | $-0.85 | $-1.25 | +32.0% | $18.3M | $16.0M | +14.7% |
| 2025-05-12 | $-1.06 | $-1.04 | -1.9% | $14.9M | $16.0M | -6.5% |
| 2025-02-10 | $-1.05 | $-1.16 | +9.5% | $17.0M | $17.2M | -1.7% |
| 2024-11-25 | $-1.36 | $-1.16 | -17.2% | $67.6M | $17.9M | +277.2% |
| 2024-08-05 | $-1.07 | $-1.49 | +28.2% | $18.0M | $17.8M | +1.0% |
| 2024-05-06 | $-1.47 | $-1.26 | -16.7% | $17.1M | $16.5M | +3.2% |
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 65.32M | 67.64M | 79.20M | 86.16M | 97.07M | 122.47M | 205.20M | 206.62M | 102.81M | 88.27M | 160.88M | 47.74M |
| Net Income | (81.89M) | (116.05M) | (133.82M) | (121.75M) | (79.00M) | (36.17M) | 46.38M | 71.96M | 17.71M | 21.67M | 78.99M | 34.44M |
| EPS | -3.84 | -5.48 | -6.38 | -5.91 | -3.92 | -1.81 | 2.37 | 3.48 | 0.93 | 1.14 | 4.23 | 1.88 |
| Total Assets | 280.73M | 376.65M | 462.27M | 380.59M | 440.86M | 490.79M | 489.83M | 414.23M | 326.64M | 281.28M | 246.01M | 155.41M |
| Total Debt | 201.06M | 226.06M | 222.44M | 26.69M | 6.83M | 9.58M | 200,000 | 293,000 | 458,000 | 531,000 | 598,000 | 200,000 |
| Cash & Equivalents | 32.30M | 37.23M | 85.39M | 43.99M | 57.21M | 87.13M | 51.23M | 63.90M | 65.67M | 16.58M | 21.73M | 30.70M |
| Operating Cash Flow | (19.27M) | (78.76M) | (103.15M) | (84.78M) | (70.00M) | 7.09M | 71.42M | 29.22M | 52.65M | 35.81M | 76.67M | 20.18M |
| Free Cash Flow | (32.17M) | (96.71M) | (112.21M) | (86.91M) | (70.75M) | 5.64M | 66.00M | 26.24M | 50.15M | 31.07M | 74.34M | 19.15M |
| FCF per Share | -1.51 | -4.57 | -5.35 | -4.22 | -3.51 | 0.28 | 3.37 | 1.27 | 2.63 | 1.64 | 3.98 | 1.04 |
| Book Value | 64.72M | 128.81M | 216.74M | 321.33M | 399.43M | 455.58M | 462.49M | 393.68M | 301.68M | 269.94M | 236.16M | 148.65M |
| Cash & ST Investments | 188.86M | 248.19M | 369.91M | 249.23M | 244.00M | 386.65M | 335.24M | 308.73M | 223.67M | 210.08M | 145.21M | 90.76M |
| ROC Equity | -1.27 | -0.90 | -0.62 | -0.38 | -0.20 | -0.08 | 0.10 | 0.18 | 0.06 | 0.08 | 0.33 | 0.23 |